|
|
||||||||
Molecular Immunology Laboratory, Samsung Biomedical Research Institute, Seoul, Korea
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Despite intensive study, the molecular mechanisms of Ig hypermutation remain unclear. One possibility is that hypermutation is a result of impaired DNA repair. Among the known DNA repair systems, the DNA mismatch repair (MMR) system deserves thorough examination for its involvement in Ig somatic hypermutation for the following reasons: First, point mutations are characteristics of somatic hypermutation in Ig V genes (reviewed in 8 . Second, unlike nucleotide excision repair (NER), which specifically removes bulky DNA adducts generated by certain types of DNA damage, the MMR system corrects point mutations introduced during DNA synthesis (reviewed in 9 . Experiments by two research groups excluded the involvement of transcription-coupled NER in Ig somatic hypermutation (10, 11). Third, inactivation of the genes encoding MMR activities results in a large increase in the spontaneous mutation rate and predisposition to tumor development (reviewed in 9 . Fourth, the connection found between MMR and transcription-coupled NER (12, 13) suggests a potential role of MMR in transcription-linked Ig somatic hypermutation. Finally, Cascalho et al. (14) showed recently that PMS2, a component of the MMR system, is involved in Ig somatic hypermutation. Interestingly, they showed that PMS2 may actually enhance hypermutation, suggesting that the MMR system may be altered in some way in hypermutating B cells such that it enhances rather than corrects somatic mutations at Ig loci.
Despite some evidence suggesting that the MMR system is involved in somatic hypermutation, it has not yet been shown definitively that this system is present and acts in the cells in which Ig hypermutation is taking place. Hence, we have assessed the function of the MMR system in human GC centroblasts. Our results show, for the first time, that GC centroblasts express all known components of the human DNA MMR system, and that their MMR system is functionally intact in correcting DNA mismatches in a strand-specific manner in vitro.
| Materials and Methods |
|---|
|
|
|---|
The human cell lines HeLa S3 (CCL2.2), HCT116 (CCL-247), and CA46 (CRL-1648) were purchased from the American Type Culture Collection (ATCC) (Manassas, VA). HCT116 and CA46 cells were grown in RPMI 1640 medium supplemented with L-glutamine (2 mM), 10% heat-inactivated FBS, penicillin (100 U/ml,), and streptomycin (0.1 mg/ml). HeLa S3 cells were grown in Hams F12 in the presence of the above supplements. All cell culture reagents were purchased from Life Technologies (Grand Island, NY).
Antibodies
Anti-CD44 mAbs (clones NKI-P1 and NKI-P2) were generous gifts of
Dr. Carl. G. Figdor (The Netherlands Cancer Institute, Amsterdam, The
Netherlands). Ascites fluids containing anti-IgD mAb (clone HJ9) or
anti-CD38 mAb (OKT10) were produced by inoculating BALB/C mice with
HJ9 or OKT10 hybridomas as described previously (15). The HJ9 hybridoma
was kindly provided by Dr. Moon H. Nahm (University of Rochester,
Rochester, NY). The OKT10 hybridoma was purchased from ATCC. The
following Abs were purchased: phycoerythrin (PE)-conjugated
anti-CD38 (Leu-17), Simultest anti-CD3-FITC and
anti-CD19-PE (Leu4/12), Simultest control
1/
1
(FITC-conjugated and PE-conjugated isotype control mouse IgG1), and
FITC-conjugated goat anti-mouse Ig (all from Becton Dickinson, San
Jose, CA); FITC-conjugated anti-IgD (Sigma, St. Louis, MO);
anti-hMSH2, anti-hMLH1, and anti-hPMS2 (all from
Calbiochem, La Jolla, CA); and anti-hPMS1 and anti-GTBP (from
Santa Cruz Biotechnology, Santa Cruz, CA).
Isolation of tonsillar B cell subsets
Human tonsillar B cell subsets were prepared as reported by Lagresle et al. (16). In brief, tonsils that had been freshly obtained from routine tonsillectomy were teased; the resulting cell suspensions were subjected to gradient centrifugation on Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) at 20°C. After washing in HBSS, tonsillar mononuclear cells were subjected to one round of T cell depletion by rosetting with 2-aminoethyl-isothiouronium bromide (Sigma, St. Louis, MO)-treated SRBCs. The resulting pool of cells contained >95% CD19+ B cells. These cells were then separated into GC centroblasts and follicular mantle (FM) B cells. GC centroblasts (CD44- B cells) were isolated by incubation with anti-CD44 Abs (NKI-P1 or NKI-P2) for 30 min on ice, followed by depletion using magnetic beads coupled to rat anti-mouse IgG1 Dynal beads (Dynal, Oslo, Norway). FM B cells were isolated by incubating the B cell pool with mouse anti-human CD38, followed by depletion using rat anti-mouse IgG1 Dynal beads. The resulting CD38- B cells were further incubated with anti-human IgD (clone HJ9) for 30 min and subsequently with microbeads conjugated with rat anti-mouse IgG1 (Miltenyi Biotec, Auburn, CA) for 15 min on ice. The IgD+ fraction was separated using a magnetic cell separation column. All separation procedures were performed at 4°C to delay the death of GC B cells by apoptosis. Isolated FM B cells (IgD+CD38-) and GC centroblasts (IgD-CD38+CD44-) were analyzed for purity on a FACS Vantage (Becton Dickinson, Sunnyvale, CA). To determine the repair activity of human primary cells, PBMCs were isolated by Ficoll-Hypaque gradient centrifugation as described above and stimulated with PMA (final 1 ng/ml; Sigma) and ionomycin (final 0.2 µM; Sigma) for 82 h.
Preparation of nuclear extracts (NEs)
NEs were prepared according to Holmes et al. (17) unless
otherwise indicated. Cell lines in the log phase of growth, resting and
stimulated human PBMCs, and human tonsillar B cell subsets (FM B cells
and GC centroblasts) that had been isolated as described above were
harvested to prepare NEs. After obtaining
0.5g of both GC
centroblasts and FM B cell pellets, the cell pellets of each type were
pooled. Each NE was frozen in small aliquots in liquid N2
and stored at -80°C.
Immunoblot analysis
Equal amounts of each NE were lysed in sample buffer (125 mM Tris-HCl (pH 6.8), 2.5% glycerol, 0.4% SDS, 1% 2-ME, and 0.01% bromophenol blue) by boiling for 3 min and were separated on a 7.5% SDS polyacrylamide gel. After electrophoresis, protein bands were transferred to a nitrocellulose membrane (Hybond enhanced chemiluminescence; Amersham, Cleveland, OH). The membrane was rinsed briefly in Tris-buffered saline (TBS), blocked with blocking solution (5% nonfat dried milk in TBS with 0.1% (v/v) Tween-20 (TBST)) for 1 h at room temperature, washed briefly with TBST, and incubated with the primary Ab (1:100) for 2 h at room temperature. The filter was rinsed extensively with TBST and subsequently incubated with the secondary Ab, horseradish-peroxidase-conjugated anti-mouse or rabbit Ig (1:5000; Amersham) for 1 h at room temperature. The filter was washed with three changes of TBST. Signals were detected by enhanced chemiluminescence (Amersham) as recommended by the manufacturer. The same blot could be used to probe with the different Abs shown in the experiments by removing the probe in stripping buffer (100 mM 2-ME, 2% SDS, and 62.5 mM Tris-HCl (pH 6.7)) at 50°C for 30 min with occasional agitation followed by washing at room temperature with large volumes of TBST.
Immunohistochemistry
Immunoperoxidase staining was performed according to the protocols provided by the manufacturer (Dako LSAB kit; Dako, Carpinteria, CA). The 5-µm thick cryosections mounted on silanized slides (Dako, Kyoto, Japan) were air dried for 1 h and fixed in ice-cold acetone for 10 min at 4°C. After rehydration and preblocking with TBST containing 1% BSA (Sigma), the slides were incubated with the primary Abs (1:50) in TBST containing 1% BSA for 16 h at 4°C in a humidified chamber. Slides were then rinsed three times in TBS and incubated with biotinylated secondary Ab. Streptavidin-conjugated peroxidase was then added, and bound peroxidase was visualized by the addition of substrate-chromogen solution. Slides were counterstained with hematoxytin (Sigma) to stain the nuclei. Immunostained slides were observed by light microscopy. For the negative controls for the immunostaining, TBST was used in place of primary Ab.
Gel shift assays
The gel shift assay was performed as reported previously
(18), with some modifications. In brief, oligonucleotide duplexes
containing a single G-T mispair or a control A-T base pair were formed
by annealing 5'-AATTCGCTAGCAAGCTTTCGATTCTAGAAATTCGGC-3' with
5'-AATTCGCCGAATTTCTAGAATCGAGAGCTTGCTAGC-3' or
5'-AATTCGCCGAATTTCTAGAATCGAAAGCTTGCTAGC-3', respectively.
Annealed duplexes were radiolabeled by filling in with Klenow DNA
polymerase (Promega, Madison, WI) in the presence of
[
-32P]deoxyATP (3000 Ci/mmol; Amersham).
32P-labeled oligonucleotide duplexes were incubated with 1
µg of each NE in 20-µL reactions containing 10 mM HEPES (pH 7.5), 1
mM EDTA, 1 mM DTT, 5 mM MgCl2, BSA (50 µg/ml), and 4%
glycerol. After a 20-min incubation on ice, 5 µL of 50% sucrose was
added and the samples were subjected to electrophoresis at room
temperature through 6% polyacrylamide in 6.7 mM Tris-acetate (pH 7.5)
and 1 mM EDTA.
Preparation of heteroduplex substrates
Phage stocks of f1 MR1 and f1 MR3 (19) were generously provided
by Dr. Paul Modrich (Duke University Medical Center, Durham, NC). G-T
and A-C heteroduplexes as well as A-T and G-C homoduplexes were
prepared according to a protocol provided by Dr. James T. Drummond
(Indiana University, Bloomington, IN). In brief, bacteriophage
f1 replicative form was isolated from infected XL1-Blue cells grown in
the presence of tetracycline (5 µg/ml; Sigma). Viral ssDNAs were
isolated from purified virions. DNA heteroduplexes were prepared by
mixing f1 duplexes (100 µg of replicative form, linearized with
Sau96I) with a fivefold molar excess of viral strands
followed by alkaline denaturation and renaturation. Circular duplexes
containing a single nick were isolated by hydroxyapatite chromatography
(Bio-Rad Laboratories, Hercules, CA) and dialyzed against 10 mM
Tris-HCl (pH 8.0) with 1 mM EDTA. The resulting dsDNA containing a
single base mismatch at position 5632 and a site-specific single-strand
break at position 5757 in the cDNA strand (refer to figure 1
in Fang
and Modrich (20)) was dissolved in distilled water.
|
MMR assays were performed as described in Holmes et al. (17). In brief, the MMR reaction (25 µL) contained 20 mM Tris-HCl (pH 7.6), 5 mM MgCl2, 1 mM glutathione, 50 µg/ml BSA, 0.1 mM of deoxynucleoside triphosphate, 1.5 mM of ATP, 24 fmol (0.1 µg) of heteroduplex DNA, and 100 µg of NE. After 20 min of incubation at 37°C, three volumes of stop solution (25 mM EDTA, 0.67% SDS, and 100 µg/ml proteinase K; (Sigma)) were added; samples were extracted twice with phenol and twice with chloroform. The DNA was collected by ethanol precipitation, dissolved in water, and digested with diagnostic restriction enzymes (Bsp106 and XhoI for the A-C heteroduplex and Bsp106 and HindIII for the G-T heteroduplex). Digestion products were separated by electrophoresis on a 1% agarose gel stained with ethidium bromide.
| Results and Discussion |
|---|
|
|
|---|
As an initial step to explore whether GC centroblasts express
components of DNA MMR and are capable of correcting mismatches, we
isolated human tonsillar GC centroblasts. As a negative control for Ig
hypermutation, naive FM B cells with nonmutated germline Ig genes were
also isolated. Because GC B cells (IgD-CD38+)
are a mixture of centroblasts and centrocytes, we further separated
centroblasts and centrocytes. From the available surface markers that
distinguish centroblasts from centrocytes, we chose anti-CD44 Abs
over anti-CD77 Abs. Feuillard et al. (21) found that anti-CD44
Ab is more reliable than anti-CD77 Ab in discriminating between
centroblasts and centrocytes. We assessed the effectiveness of this
separation method by FACS analysis (Fig. 1
). More than 97% of CD44-
B cells are IgD-CD38+ (Fig. 1
B) and show a high level of CD77 expression (data
not shown). Thus, negative selection of B cells not expressing CD44 on
their surface yields a preparation of GC B cells that is selectively
depleted of centrocytes. We also routinely obtained FM B cells with
>95% purity (Fig. 1
C).
Expression of MMR proteins in human GC and FM B cells
Defects in MMR result in an elevated rate of spontaneous
mutations, termed the "mutator phenotype" (22). Among the known
human MMR proteins, hMSH2 is known to initiate MMR by recognizing
mispairs after forming specific mispair-binding complexes with hMSH3 or
hMSH6 (GTBP) (18, 23, 24). The hMLH1/hPMS2 heterodimer (hMutL
) is
also required for functional MMR (25). NEs derived from
immunomagnetically sorted GC centroblasts and FM B cells were used to
examine the presence of human MMR proteins. MMR-proficient HeLa cells
(17, 26) are included as a positive control for each human MMR protein.
An immunoblot with increasing amounts of protein from each NE shows the
expression of those five MMR proteins in GC centroblasts (Fig. 2
). The intensity of each signal obtained
from the NE derived from GC centroblasts was comparable with that of
MMR-proficient HeLa NE. Alternatively, FM B cells expressed only low
basal levels of hMSH2 and hMLH1 proteins and similar levels of the
other three proteins.
|
|
The human MSH2/GTBP heterodimer that is present in HeLa cells
binds to G-T mispairs with high affinity in vitro (18, 23); hMSH2 is
reportedly central to all mismatch recognition (24). Based on our
immunoblot analysis, we tested whether the mismatch-binding proteins
present in GC centroblasts are capable of binding to a mismatched base
pair using gel mobility shift assays (Fig. 4
). The radiolabeled oligoduplex probe
containing a single G-T mismatch yields a single bound complex with NEs
prepared from both GC centroblasts and HeLa cells. The unlabeled
oligonucleotide duplex containing the G-T mispair abolishes this
DNA-protein interaction. When the A-T homoduplex was used as a probe in
the same assay, some bound complex was detected; however, the signal
was much lower. This result suggests that the mismatch-binding proteins
in GC centroblasts recognize mismatched DNA substrates and initiate
repair.
|
To determine whether the MMR system of GC centroblasts is
functionally intact, we used an in vitro MMR assay that was developed
in Dr. Paul Modrichs laboratory. We examined whether NE from human GC
centroblasts contains MMR activity that is capable of correcting
mispairs in a strand-specific manner. The DNA MMR efficiency of GC
centroblasts was compared with those of other NEs using diagnostic
restriction enzymes that cut only when the mismatch was repaired on the
nicked strand. Repair products were detected in both HeLa cells and in
the Burkitts lymphoma B cell line CA46 (Fig. 5
). HCT116, a colon carcinoma cell line
that is defective in the expression of hMLH1 protein, was included as a
negative control. To determine the sensitivity of this assay system in
detecting the repair activity of primary human B cells, we also
measured the repair activity of stimulated human PBMCs and resting
human PBMCs. A comparable level of repair activity was detected in
stimulated PBMCs, whereas no such activity is detected in resting PBMCs
(Fig. 5
). We detected MMR products in the NE prepared from isolated
human GC centroblasts using the same assay system. Our findings
indicate that the NE of GC centroblasts is functionally proficient in
correcting mismatches in a naked heteroduplex DNA in a strand-specific
manner in vitro.
|
Somatic hypermutation within a restricted region of the Ig genes in GC
centroblasts in the presence of functional MMR components suggests that
MMR is not responsible for inducing Ig hypermutation. It is possible
that a specific chromatin structure at the Ig loci or the presence of a
mutator factor might be involved in introducing mutations into Ig V
genes. The mechanism of Ig somatic hypermutation is still unknown, but
several lines of evidence suggest that it is linked to
transcription (33, 34, 35). Among the important factors involved in
the transcription of Ig genes, the involvement of the Ig promoter and
the polymerase II system can be ruled out. The Ig promoter can
be replaced by a heterologous promoter such as the ß-globin promoter
(36), and the polymerase II system is universal. On the other hand, Ig
enhancers and the nuclear matrix attachment region (MAR) are
essential for a full Ig hypermutation (36), although the mechanism of
their actions in this process is unknown. A recent experiment
demonstrated that the targeting of Ig hypermutation in the Ig
gene
is dependent on both the nuclear MAR that flanks the intronic enhancer
and the core and flanking sequences of the 3' enhancer element (35). Ig
enhancers and nuclear MARs with their associated cluster of binding
sites for topoisomerase II may initiate hypermutation by promoting the
formation of single-strand nicks, as suggested by Neuberger and
Milstein (6).
In conclusion, we have examined the function of the MMR system in GC centroblasts. Our finding of the presence of functional MMR activity in isolated human tonsillar GC centroblasts provides the first evidence that hypermutating B cells do not have a general suppression of MMR.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Kyoungsook Park, Molecular Immunology Laboratory, Samsung Biomedical Research Institute, Ilwon-dong 50, Kangnam-ku, Seoul, Korea, 135-230. E-mail address: ![]()
3 Current address: Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, Baltimore, MD 21205. ![]()
4 Abbreviations used in this paper: GC, germinal center; FM, follicular mantle; MAR, matrix attachment region; MMR, mismatch repair; NE, nuclear extract; NER, nucleotide excision repair. ![]()
Received for publication June 5, 1998. Accepted for publication August 6, 1998.
| References |
|---|
|
|
|---|
transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers. EMBO J. 16:3987.[Medline]
gene: critical role for the intron enhancer/matrix attachment region. Cell 77:239.[Medline]
This article has been cited by other articles:
![]() |
C. E. Schrader, W. Edelmann, R. Kucherlapati, and J. Stavnezer Reduced Isotype Switching in Splenic B Cells from Mice Deficient in Mismatch Repair Enzymes J. Exp. Med., August 2, 1999; 190(3): 323 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kim, G. Bozek, J. C. Lo, and U. Storb Different Mismatch Repair Deficiencies All Have the Same Effects on Somatic Hypermutation: Intact Primary Mechanism Accompanied by Secondary Modifications J. Exp. Med., July 1, 1999; 190(1): 21 - 30. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |